Distortion product otoacoustic emissions after intratympanic gentamicin therapy for unilateral Ménière's disease

Audiology and Neurotology

Volumn 10, Issue 2, 2005, Pages 69-78

  Perez, Nicolas ^a,c   Boleas, Ma Soledad ^a   Martin, Eduardo ^b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b Hospital Casa de Salud Valencia   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Deafness; Gentamicin; Hearing loss; M ni re's disease; Ototoxicity; Vertigo

Indexed keywords

GENTAMICIN; ANTIINFECTIVE AGENT;

ADULT; AMPLITUDE MODULATION; ARTICLE; AUDIOMETRY; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); DISTORTION PRODUCT OTOACOUSTIC EMISSION; FEMALE; HEAD AND NECK SURGERY; HEARING; HUMAN; MALE; MENIERE DISEASE; OTOACOUSTIC EMISSION; OTORHINOLARYNGOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SPEECH; SPEECH DISCRIMINATION; VESTIBULAR FUNCTION; CHEMICALLY INDUCED DISORDER; COCHLEA; DRUG EFFECT; HEARING LOSS; INJECTION; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PURE TONE AUDIOMETRY; RISK FACTOR; SPEECH AUDIOMETRY; SPONTANEOUS OTOACOUSTIC EMISSION; TREATMENT OUTCOME; VESTIBULE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SCREENING; PATIENT; SCORING SYSTEM;

ANTI-BACTERIAL AGENTS; AUDIOMETRY, PURE-TONE; AUDIOMETRY, SPEECH; COCHLEA; FEMALE; GENTAMICINS; HEARING LOSS; HUMANS; INJECTIONS; MALE; MENIERE'S DISEASE; MIDDLE AGED; OTOACOUSTIC EMISSIONS, SPONTANEOUS; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; VESTIBULE;

EID: 19944370512     PISSN: 14203030     EISSN: None     Source Type: Journal    
DOI: 10.1159/000083362     Document Type: Article

References (25)

1. Cianfrone G, Ralli G, Fabbricatore M, Altissimi G, Nola G: Distortion product otoacoustic emissions in Ménière's disease. Scand Audiol 2000;29:111-119.
2. Committee on Hearing and Equilibrium: Guidelines for diagnosing the evaluation of therapy in Ménière's disease. Otolaryngol Head Neck Surg 1995;113:181-185.
3. Conlon BJ, McSwain SD, Smith DW: Topical gentamicin and ethacrynic acid: Effects on cochlear function. Laryngoscope 1998;108:1087-1089.
4. De Kleine E, Mateijsen DJM, Wit HP, Albers FWJ: Evoked otoacoustic emissions in patients with Ménière's disease. Otol Neurotol 2002;23:510-516.
5. Enander A, Stahle J: Hearing in Ménière's disease. A study of pure-tone audiograms in 334 patients. Acta Otolaryngol 1967;64:543-556.
6. Fetterman BL: Distortion-product otoacoustic emissions and cochlear microphonics: Relationships on patients with and without endolymphatic hydrops. Laryngoscope 2001;111:946-954.
7. Friberg U, Stahle J Svedberg A: The natural course of Ménière's disease. Acta Otolaryngol Suppl 1984;406:72-77.
8. Hoffer ME, Allen K, Kopke RD, Weisskopf P, Gottshall K, Wester D: Transtympanic versus sustained-release administration of gentamicin: Kinetics, morphology and function. Laryngoscope 2001;111:1343-1357.
9. Hotz MA, Harris FP, Probst R: Otoacoustic emissions: An approach for monitoring aminoglycoside-induced ototoxicity. Laryngoscope 1994;104:1130-1134.
10. Hwang JH, Tan CT, Chiang CW, Liu TC: Acute effects of alcohol on auditory thresholds and distortion-product Otoacoustic emissions in humans. Acta Otolaryngol 2003;123:936-940.
11. Imamura S, Adams J: Distribution of gentamicin in the guinea pig inner era after local or systemic application. J Assoc Res Otolaryngol 2003a;4:176-195.
12. Imamura S, Adams J: Changes in cytochemistry of sensory and nonsensory cells in gentamicin-treated cochleas. J Assoc Res Otolaryngol 2003b;4:196-218.
13. Katsarkas A, Ayukawa H: Hearing loss due to aging (presbycusis). J Otolaryngol 1986;15:239-244.
14. Kobayashi M, Umemura M, Sone M, Kakashima T: Differing effects on the inner ear of three gentamicin compounds: GM-C1, -C2 and -C1a*. Acta Otolaryngol 2003;123:916-922.
15. Lonsbury-Martin B, Martin GK: Otoacoustic emissions. Curr Opin Otolaryngol Head Neck Surg 2003;11:361-366.
16. Martin E, Perez N: Hearing loss after intratympanic gentamicin therapy for unilateral Ménière's disease. Otol Neurotol 2003;24:800-806.
17. Mizukoshi K, Watanabe Y, Shojaku H, Matsunaga T, Tokumasu K: Preliminary guideliness for reporting treatment results in Ménière's disease conducted by the Committee of the Japanese Society for Equilibrium Research. Acta Otolaryngol Suppl 1995;519:211-215.
18. Nakashima T, Teranishi M, Hibi T, Kobayashi M, Umemura M: Vestibular and cochlear toxicity of aminoglycosides: A review. Acta Otolaryngol 2000;120:904-911.
19. Orts Alborch M, Morant Ventura A, Garcia Callejo J, Ferrer Baixauli F, Martinez Beneito MP, Marco Algarra J: Monitoring drug ototoxicity with distortion products. Acta Otorrinolaringol Esp 2000;51:387-395.
20. Ozturan O, Lam S: The effect of haemodialysis on hearing using pure-tone audiometry and distortion-product otoacoustic emissions. ORL 1998;60:306-313.
21. Perez N, Espinosa JM, Fernández S, Garcia-Tapia R: Use of distortion-product otoacoustic emissions for auditory evaluation in Ménière's disease. Eur Arch Otorhinolaryngol 1997;254:329-342.
22. Perez N, Martin E, Garcia-Tapia R: Intratympanic gentamicin for intractable Ménière's disease. Laryngoscope 2003;113:456-464.
23. Preyer S, Baisch A, Less D, Gummer AW: Distortion product otoacoustic emissions in human hypercholesterolemia. Hear Res 2001;152:139-151.
24. Ruckenstein MJ, Shea J: Clinical manifestations of Méniè re's disease: in Harris JP (ed): Ménière's Disease. St Louis, Kugler Publications, 1999, pp 263-266.
25. Stavroulaki P, Nikolopoulos TP, Psarommatis I, Apostolopoulos N: Hearing evaluation with distortion-product otoacoustic emissions in young patients undergoing haemodialysis. Clin Otolaryngol 2001;26:235-242.